This is a preview of subscription content, log in via an institution to check access.
Reference
Lee T-Y, et al. Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan's health care system. European Journal of Health Economics : 6 Jun 2020. Available from: URL: https://doi.org/10.1007/s10198-020-01207-7
Rights and permissions
About this article
Cite this article
Cost effectiveness of inotuzumab ozogamicin in Taiwan. PharmacoEcon Outcomes News 855, 9 (2020). https://doi.org/10.1007/s40274-020-6874-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6874-6